Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Solid Biosciences Inc. Common Stock

SLDB

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Last trade $6.33
Day change -$0.15 (-2.31%)
Day range $6.11 – $6.61
Volume 625,905
Market cap $723M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$723.24M
Price / earnings
—
Price / book
2.11×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.71×

Profitability

Earnings per share
-$1.93
Return on assets
-55.21%
Return on equity
-62.92%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
11.99×
Quick ratio
11.99×
Cash ratio
4.14×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$200.3M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SLDB, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$14.06M$13.12M$11.17M$11.27M$9.2M$9.28M$9.14M$9.13M
Research and development$43.6M$44.27M$46.14M$38.14M$38.86M$32.42M$30.91M$30.77M
Total operating expenses$57.66M$57.38M$57.31M$49.4M$48.06M$41.69M$40.05M$39.9M
Operating income-$57.66M-$57.38M-$57.31M-$49.4M-$48.06M-$41.69M-$40.05M-$39.9M
Interest expense$0$0$0-$5K$336K-$60K-$68K-$75K
Income before taxes-$53.95M-$54.8M-$56.74M-$49.79M-$45.78M-$39.48M-$39.28M-$42.6M
Income taxes$0$0$0$0$0$0$0$0
Net income-$53.95M-$54.8M-$56.74M-$49.79M-$45.78M-$39.48M-$39.28M-$42.6M
Net income attributable to common shareholders-$53.95M-$54.8M-$56.74M-$49.79M-$45.78M-$39.48M-$39.28M-$42.6M
EBITDA-$57.24M-$56.99M-$56.91M-$48.94M-$47.68M-$41.31M-$39.65M-$39.41M
Basic earnings per share-$0.36-$0.38-$0.52-$0.52-$0.48-$0.42-$0.59-$1.00
Diluted earnings per share-$0.36-$0.38-$0.52-$0.52-$0.48-$0.42-$0.59-$1.00

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 28, 20221-for-15reverse split